Tempest Therapeutics (TPST) Total Current Liabilities (2011 - 2026)

Tempest Therapeutics has disclosed Total Current Liabilities across 16 years of filings, most recently posting $4.4 million for Q2 2026.

• In Q2 2026, Total Current Liabilities fell 37.68% year-over-year to $4.4 million; the TTM figure through Jun 2026 stood at $4.4 million (down 37.68% YoY), while the FY2025 annual figure was $3.3 million, down 76.69% from the prior year.
• Total Current Liabilities came in at $4.4 million for Q2 2026 at Tempest Therapeutics, up from $3.3 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $24.1 million in Q3 2022 to a low of $3.3 million in Q4 2025.
• Average Total Current Liabilities over 5 years is $11.3 million, with a median of $9.4 million recorded in 2023.
• Year-over-year, Total Current Liabilities soared 287.86% in 2022 and plunged 76.69% in 2025.
• Over 5 years, Total Current Liabilities stood at $7.3 million in 2022, then advanced by 29.33% to $9.4 million in 2023, then soared by 51.1% to $14.2 million in 2024, then sank by 76.69% to $3.3 million in 2025, then surged by 34.28% to $4.4 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $4.4 million in Q2 2026, $3.3 million in Q4 2025, and $3.5 million in Q3 2025.